
Giovanni Franchin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8132905/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Active Site Residues of Cyclophilin A Are Crucial for Its Signaling Activity via CD147. Journal of Biological Chemistry, 2002, 277, 22959-22965.	1.6	283
2	Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 2003, 102, 311-319.	0.6	199
3	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 11-15.	0.4	174
4	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. International Journal of Radiation Oncology Biology Physics, 2003, 55, 78-92.	0.4	112
5	Detection and Restaging of Residual and/or Recurrent Nasopharyngeal Carcinoma after Chemotherapy and Radiation Therapy: Comparison of MR Imaging and FDG PET/CT. Radiology, 2008, 249, 203-211.	3.6	111
6	Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine, 1998, 16, 768-774.	1.7	104
7	Etoposide (VP-16-213) in malignant brain tumors: a phase II study Journal of Clinical Oncology, 1984, 2, 432-437.	0.8	94
8	Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma a randomized study. Cancer, 1990, 65, 400-404.	2.0	90
9	Radiotherapy for patients with early-stage glottic carcinoma. Cancer, 2003, 98, 765-772.	2.0	80
10	Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1114-1119.	0.4	79
11	Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer, 2014, 83, 78-82.	0.9	76
12	Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Critical Reviews in Oncology/Hematology, 2005, 53, 71-80.	2.0	73
13	Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncology, 2011, 47, 541-545.	0.8	70
14	Lipopolysaccharide Inhibits HIV-1 Infection of Monocyte- Derived Macrophages Through Direct and Sustained Down-Regulation of CC Chemokine Receptor 5. Journal of Immunology, 2000, 164, 2592-2601.	0.4	66
15	Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunology, Immunotherapy, 2006, 55, 23-30.	2.0	63
16	Combined effect of tobacco smoking and alcohol drinking in the risk of head and neck cancers: a re-analysis of case–control studies using bi-dimensional spline models. European Journal of Epidemiology, 2016, 31, 385-393.	2.5	60
17	Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. Journal of Thoracic Oncology, 2012, 7, 1862-1866.	0.5	53
18	The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy. Oral Oncology, 2017, 67, 175-182.	0.8	50

#	Article	IF	CITATIONS
19	Pulse steroids: How much is enough?. Autoimmunity Reviews, 2006, 5, 111-113.	2.5	47
20	Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. International Journal of Radiation Oncology Biology Physics, 2015, 93, 606-613.	0.4	42
21	Radiation treatment of glottic squamous cell carcinoma, stage I and II: Analysis of factors affecting prognosis. International Journal of Radiation Oncology Biology Physics, 1998, 40, 541-548.	0.4	37
22	Intermittent pelvic arterial infusion with peptichemio, doxorubicin, and cisplatin for locally advanced and recurrent carcinoma of the uterine cervix. Cancer, 1987, 60, 25-30.	2.0	36
23	An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2017, 23, 3769-3780.	3.2	36
24	A follow-up study of determinants of second tumor and metastasis among subjects with cancer of the oral cavity, pharynx, and larynx. Journal of Clinical Epidemiology, 1996, 49, 367-372.	2.4	35
25	Long-Term Results of Conventional Radiotherapy versus Accelerated Hyperfractionated Radiotherapy versus Concomitant Radiotherapy and Chemotherapy in Locoregionally Advanced Carcinoma of the Oropharynx. Tumori, 2006, 92, 41-54.	0.6	35
26	Role of Rho family GTPases in CCR1- and CCR5-induced actin reorganization in macrophages. Biochemical and Biophysical Research Communications, 2005, 331, 909-916.	1.0	33
27	Spontaneous T cell responses to Epsteinâ€Barr virusâ€encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. International Journal of Cancer, 2008, 123, 1100-1107.	2.3	32
28	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 58.	1.8	32
29	The efficacy of radiotherapy in the treatment of intraocular metastases. British Journal of Radiology, 1993, 66, 699-702.	1.0	31
30	The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncology, 1999, 35, 203-208.	0.8	30
31	Anti-DNA antibodies cross-react with C1q. Journal of Autoimmunity, 2013, 44, 34-39.	3.0	27
32	Dose to the skin in helical tomotherapy: Results of inÂvivo measurements with radiochromic films. Physica Medica, 2013, 29, 304-311.	0.4	26
33	Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms. Oral Oncology, 1998, 34, 119-122.	0.8	25
34	The EORTC quality of life questionnaire-head and neck 35 in Italian laryngectomized patients. European organization for research and treatment of cancer. Quality of Life Research, 2000, 9, 1147-1153.	1.5	25
35	A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anti-Cancer Drugs, 2008, 19, 739-744.	0.7	23
36	Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. Nutrients, 2021, 13, 1277.	1.7	23

#	Article	IF	CITATIONS
37	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infectious Agents and Cancer, 2007, 2, 5.	1.2	21
38	A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients. Cancer, 1984, 54, 393-396.	2.0	20
39	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. Cancer, 1994, 74, 978-984.	2.0	20
40	Brief report: Prognostic importance of cellular DNA content in T1-2 NO laryngeal squamous cell carcinomas treated with radiotherapy. Laryngoscope, 1995, 105, 649-652.	1.1	20
41	Post-chikungunya rheumatic disorders in travelers after return from the Caribbean. Travel Medicine and Infectious Disease, 2016, 14, 21-25.	1.5	20
42	Splenic irradiation in chronic lymphocytic leukemia. A 10-year experience at a single institution. Cancer, 1987, 60, 2624-2628.	2.0	19
43	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Cancer Immunology Research, 2016, 4, 431-440.	1.6	19
44	Radiation Therapy Combined with Chemotherapy for Inoperable Pancreatic Carcinoma. Tumori, 1991, 77, 61-64.	0.6	18
45	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. International Journal of Cancer, 2009, 125, 1358-1364.	2.3	18
46	Multiple fraction per day radiation therapy for inoperable esophageal cancer. International Journal of Radiation Oncology Biology Physics, 1988, 14, 855-860.	0.4	17
47	Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study. Radiotherapy and Oncology, 1992, 23, 241-244.	0.3	17
48	Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy. Biomarkers, 2015, 20, 422-428.	0.9	17
49	Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and head and neck cancers risk. Oral Oncology, 2017, 64, 59-64.	0.8	17
50	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer, 2013, 13, 513.	1.1	16
51	Squamous cell carcinoma of the hypopharynx treated with surgery and radiotherapy. Journal of Laryngology and Otology, 2002, 116, 24-8.	0.4	15
52	miRâ $\in 9$ modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Molecular Medicine, 2021, 13, e12872.	3.3	15
53	Squamous cell carcinoma of the posterior pharyngeal wall: characteristics compared with the lateral wall. Journal of Laryngology and Otology, 1995, 109, 120-125.	0.4	13
54	Changes in presentation and survival of head and neck carcinomas in Northeastern Italy, 1975-1998. Cancer, 2002, 95, 540-552.	2.0	13

#	Article	IF	CITATIONS
55	Postoperative reduced dose of cisplatin concomitant with radiation therapy in high―risk head and neck squamous cell carcinoma. Cancer, 2009, 115, 2464-2471.	2.0	13
56	Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: A prospective mono-institutional Italian experience. Tumori, 2011, 97, 614-619.	0.6	13
57	Fiber Intake and Risk of Nasopharyngeal Carcinoma: A Case-Control Study. Nutrition and Cancer, 2013, 65, 1157-1163.	0.9	13
58	Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1368-1376.	0.4	13
59	Accelerated split course regimen in the treatment of brain metastases. Radiotherapy and Oncology, 1988, 12, 39-44.	0.3	12
60	Correlation of a hypoxia based tumor control model with observed local control rates in nasopharyngeal carcinoma treated with chemoradiotherapy. Medical Physics, 2010, 37, 1533-1544.	1.6	12
61	Carcinoma of the nasal vestibule: Report of 12 cases. Journal of Laryngology and Otology, 1990, 104, 9-11.	0.4	11
62	Nasopharyngeal cancer WHO type II-III: monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy. Oral Oncology, 2002, 38, 137-144.	0.8	11
63	Metabolic disorders and the risk of nasopharyngeal carcinoma: a case–control study in Italy. European Journal of Cancer Prevention, 2018, 27, 180-183.	0.6	11
64	Direct health-care cost of head and neck cancers: a population-based study in north-eastern Italy. Medical Oncology, 2019, 36, 31.	1.2	11
65	Evaluation of hospital care in a radiotherapy department in North-eastern Italy. European Journal of Cancer & Clinical Oncology, 1991, 27, 1253-1258.	0.9	10
66	Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1992, 24, 573-574.	0.4	10
67	Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study. Cancer, 1995, 75, 1025-1029.	2.0	10
68	Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. Journal of Leukocyte Biology, 2003, 74, 781-790.	1.5	10
69	Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncology, 2005, 41, 526-533.	0.8	10
70	Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. European Archives of Oto-Rhino-Laryngology, 2009, 266, 719-726.	0.8	10
71	Helical Tomotherapy in Children and Adolescents: Dosimetric Comparisons, Opportunities and Issues. Cancers, 2011, 3, 3972-3990.	1.7	10
72	Feasibility of Total Body Irradiation in Chronic Lymphocytic Leukemia and Low-Grade Non-Hodgkin's Lymphomas. Cancer Investigation, 1991, 9, 403-407.	0.6	9

#	Article	IF	CITATIONS
73	Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. Journal of Cellular Physiology, 2012, 227, 233-238.	2.0	9
74	Effectiveness of selective neck dissection in head and neck cancer: The experience of two <scp>l</scp> talian centers. Laryngoscope, 2015, 125, 1849-1855.	1.1	9
75	Lowâ€dose radiotherapy in diffuse large Bâ€cell lymphoma. Hematological Oncology, 2017, 35, 472-479.	0.8	9
76	Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature. Hormones, 2017, 13, 322-327.	0.9	9
77	Treatment of recurrent high-grade gliomas with CliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori, 2011, 97, 614-9.	0.6	9
78	Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study. International Journal of Radiation Oncology Biology Physics, 1982, 8, 1051-1054.	0.4	8
79	Results of Three Consecutive Combined Treatments for Malignant Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 437-443.	0.6	8
80	β-Chemokine production in CD40L-stimulated monocyte-derived macrophages requires activation of MAPK signaling pathways. Cytokine, 2003, 23, 53-63.	1.4	8
81	Rheumatology fellows' perception on training and careers in academia: The American College of Rheumatology Fellow Research and Academic Training Survey. Arthritis and Rheumatism, 2009, 61, 266-273.	6.7	8
82	Postoperative Radiotherapy in Locally Advanced Head and Neck Cancer. Tumori, 1989, 75, 47-52.	0.6	7
83	Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer. Gynecologic Oncology, 1991, 41, 206-211.	0.6	7
84	Endometrial Stage I Carcinoma Treated with Surgery and Adjuvant Irradiation: A Retrospective Analysis. Tumori, 1995, 81, 256-260.	0.6	7
85	Collapsing Focal Segmental Glomerulosclerosis in a Patient with Systemic Lupus Erythematosus. Case Reports in Medicine, 2014, 2014, 1-5.	0.3	7
86	Radiation recall dermatitis induced by COVID-19 vaccination in breast cancer patients treated with postoperative radiation therapy. Breast, 2022, 65, 49-54.	0.9	7
87	VM26 in malignant hematological diseases. Cancer Chemotherapy and Pharmacology, 1982, 7, 173-4.	1.1	6
88	Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB–IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. Oral Oncology, 2011, 47, 905-909.	0.8	6
89	Optimizing Craniospinal Radiotherapy Delivery in a Pediatric Patient Affected by Supratentorial PNET: A Case Report. Tumori, 2010, 96, 316-321.	0.6	5
90	Etanercept-induced myositis: do we have to stop it? A surprising outcome. BMJ Case Reports, 2016, 2016, bcr2015213577.	0.2	4

#	ARTICLE	IF	CITATIONS
91	Phase II study of VM 26 in extensively pretreated breast cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1984, 7, 451-452.	0.6	3
92	Combined Modality Treatment of Locally Advanced Lung Cancer. Tumori, 1998, 84, 259-269.	0.6	3
93	The Structure and Derivation of Antibodies and Autoantibodies. , 2013, , 76-95.		3
94	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 378-384.	0.6	3
95	Treatment of grade III and IV astrocytoma with high-dose irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 1984, 7, 265-268.	0.6	2
96	Kaposi's Sarcoma in a Heart Transplant Patient. Acta Oncológica, 1998, 37, 769-770.	0.8	2
97	Pathogenesis of SLE: implications for rational therapy. Drug Discovery Today Disease Mechanisms, 2004, 1, 303-308.	0.8	2
98	Optimizing craniospinal radiotherapy delivery in a pediatric patient affected by supratentorial PNET: a case report. Tumori, 2010, 96, 316-21.	0.6	2
99	Adriamycin, Bleomycin, Vinblastine and DTIC in Advanced Diffuse Lymphocytic Poorly Differentiated Lymphoma. Tumori, 1981, 67, 477-481.	0.6	1
100	Hyperthermia in Clinical Practice: Preliminary Results and Current Problems in the Treatment of 21 Patients. Tumori, 1992, 78, 262-265.	0.6	1
101	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. Journal of Radiotherapy, 2014, 2014, 1-7.	0.2	1
102	Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders. Medical Science Monitor, 2021, 28, e934267.	0.5	1
103	Knee Arthrocentesis in Adults. Journal of Visualized Experiments, 2022, , .	0.2	1
104	Ovarian Cancer: Ten-Year Experience in a Community Hospital. Tumori, 1987, 73, 381-388.	0.6	0
105	Variations in Tumor Levels of Cis-Platinum through a Course of Fractionated Radiotherapy in Patients with Non-Small Cell Lung Cancer. Tumori, 1997, 83, 904-906.	0.6	0
106	IMRT with concomitant boost versus conventional radiation in the setting of sequential chemoradiotherapy for oropharyngeal cancer. Journal of Radiotherapy in Practice, 2014, 13, 418-427.	0.2	0
107	WE-C-AUD B-01: Tumor Control Probability of Undifferentiated Nasopharyngeal Cancer. Medical Physics, 2008, 35, 2933-2933.	1.6	0